Close Menu

GSK

NEW YORK (GenomeWeb) – Genedata said this week that GlaxoSmithKline's biopharma research and development arm has selected its Genedata Biologics software to handle data management and workflow support needs.

NEW YORK (GenomeWeb) – Metabolon today announced a collaboration to provide metabolomic profiling services to GlaxoSmithKline.

Originally published April 29.
NEW YORK (GenomeWeb) — In garnering rights to GlaxoSmithKline's portfolio of oncology drugs, Novartis has access to several newly launched personalized cancer agents that the company hopes to drive to blockbuster status in coming years.

UK's CHMP Grants Positive Review of MEK Inhibitor Melanoma Drug Mekinist
The UK's Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission grant marketing authorization to GlaxoSmithKline's Mekinist (trametinib).

NEW YORK (GenomeWeb News) – In an effort to address the high failure rate of drug candidates in clinical studies, the Wellcome Trust Sanger Institute, the European Bioinformatics Institute, and GlaxoSmithKline have partnered to create a new center that will use genomics and big data technologies

A sequencing study of a bladder cancer patient from a Phase I clinical trial of Novartis' mTOR inhibitor Afinitor (everolimus) in combination with GlaxoSmithKline's VEGF inibitor Votrient (pazopanib) has found the most likely culprit for that patient's extraordinary response to

While much attention has been focused on the use of microRNAs for diagnostic applications, a number of pharmaceutical firms have been exploring the non-coding RNAs' potential as biomarkers of drug-related toxicity.

This is the second article in a two-part feature on the state of personalized drug development. The first part, published last week, focused on the scientific challenges facing the industry. This latest piece is about the evolving regulatory and financial environment and recent advances in the field.

In 2013, the top selling pharmacogenetically targeted drugs were well-known personalized medicine products, Herceptin and Gleevec.

Pages

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.